UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/590,958	08/25/2006	Petra Cirpus	13987-00019-US	9681
	7590 06/24/200 BOVE LODGE & HUT	EXAMINER		
PO BOX 2207		MCELWAIN, ELIZABETH F		
WILMINGTON, DE 19899			ART UNIT	PAPER NUMBER
			1638	
			MAIL DATE	DELIVERY MODE
			06/24/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/590,958	CIRPUS ET AL.			
Office Action Summary	Examiner	Art Unit			
	Elizabeth F. McElwain	1638			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	l. lely filed the mailing date of this communication. (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on <u>20 Ag</u> This action is FINAL . 2b)⊠ This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) ☐ Claim(s) 1-24 is/are pending in the application. 4a) Of the above claim(s) 10-24 is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-9 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or Application Papers 9) ☐ The specification is objected to by the Examine 10) ☐ The drawing(s) filed on 25 August 2006 is/are:	n from consideration. r election requirement. r. a)⊠ accepted or b)⊡ objected t	•			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11)☐ The oath or declaration is objected to by the Ex		, ,			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	te			

Art Unit: 1638

DETAILED ACTION

Election/Restrictions

1. Applicant's election with traverse of Group I, claims 1-9 in the reply filed on April 20, 2009 is acknowledged. The traversal is on the ground(s) that no lack of unity was found in the PCT. This is not found persuasive because this is a separate application that is searched and examined under US practice and the Examiner has clearly shown that there is no special technical feature that unites the claims. The additional groups would require a burden for search and examination, wherein the search for oils and products comprising oils would require additional search in other classes. The Examiner has withdrawn the portion of the restriction requirement requesting the election of a SEQ ID number, given that there are no sequences presently listed in the claims. However, if SEQ ID numbers are introduced into the claims at a later time in prosecution, then this portion of the restriction requirement will be reinstated.

The requirement is still deemed proper and is therefore made FINAL.

Claim Objections

Claim 6 is objected to for the recitation of "a vegetable plant or an ornamental", which would be more clearly stated as "a vegetable producing plant or an ornamental plant", for example.

Specification

2. The disclosure is objected to because of the following informalities: it is unclear if there is a brief description provided for each of the drawings. It is noted that some of the drawings are described at pages 66-68 of the specification. However, not all of the figures are described here and there is no heading provided.

Art Unit: 1638

3. In addition, the MPEP suggests a layout for the specification along with preferred

headings for each section, which have not been used in the present specification.

Appropriate correction is required.

The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant's use.

Arrangement of the Specification

As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase "Not Applicable" should follow the section heading:

- (a) TITLE OF THE INVENTION.
- (b) CROSS-REFERENCE TO RELATED APPLICATIONS.
- (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT.
- (d) THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT.
- (e) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC.
- (f) BACKGROUND OF THE INVENTION.
 - (1) Field of the Invention.
 - (2) Description of Related Art including information disclosed under 37 CFR 1.97 and 1.98.
- (g) BRIEF SUMMARY OF THE INVENTION.
- (h) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S).
- (i) DETAILED DESCRIPTION OF THE INVENTION.
- (j) CLAIM OR CLAIMS (commencing on a separate sheet).
- (k) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet).
- (1) SEQUENCE LISTING (See MPEP § 2424 and 37 CFR 1.821-1.825. A "Sequence Listing" is required on paper if the application discloses a nucleotide or amino acid sequence as defined in 37 CFR 1.821(a) and if the required "Sequence Listing" is not submitted as an electronic document on compact disc).

Double Patenting

4. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection

Art Unit: 1638

is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

5. Claims 1-9 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 3 of copending Application No. 10/566,944. Although the conflicting claims are not identical, they are not patentably distinct from each other because claim 3 of Application No. 10/566,944 is drawn to a method of making polyunsaturated fatty acids in an organism by transforming the organism with an omega-3 desaturase coding sequence in combination with other fatty acid biosynthesis genes., which would be obvious in view of the present claims drawn to to a method of making polyunsaturated fatty acids in an organism by transforming the organism with an omega-3 desaturase coding sequence and optionally together with other fatty acid biosynthesis genes

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Art Unit: 1638

Claim Rejections - 35 USC § 102

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the

basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on

sale in this country, more than one year prior to the date of application for patent in the United States.

7. Claims 1-9 are rejected under 35 U.S.C. 102(b) as being anticipated by Knutzon (US

Patent 6,459,018).

8. The claims are drawn to a method of making polyunsaturated fatty acids (PUFAs) in an

organism by transforming the organism with an omega-3 desaturase coding sequence in

combination with other fatty acid biosynthesis genes, wherein the organism may be a plant, such

as Brassica, wherein the oil extracted from the plant has the PUFA in a concentration of at least

5% by weight of the total lipid content. It is noted that delta-15 desaturase is another name for

omega-3 desaturase.

9. Knutzon (US Patent 6,459,018) teaches a method of making polyunsaturated fatty acids

(PUFAs) in a plant by transforming a Brassica plant with an omega-3 desaturase coding

sequence, and further in combination with other fatty acid biosynthesis genes, such as a delta-6

desaturase, wherein the PUFA extracted from the Brassica plant is stearidonic acid (18:4) in a

concentration of greater than 7% (see the Detailed Description at paragraphs 40-49 and Table 2).

Conclusion

No claims are allowed.

Art Unit: 1638

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Elizabeth F. McElwain whose telephone number is (571) 272-

0802. The examiner can normally be reached on increased flex time.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Anne Marie Grunberg can be reached on (571) 272-0975. The fax phone number for

the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

EFM

/Elizabeth F. McElwain/

Primary Examiner, Art Unit 1638